Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Repeated Doses of Glucagon on Animal Starch in the Liver

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 diabetes mellitus diagnosed for at least 6 months~* Current usage of subcutaneous insulin pump treatment~* Age 18-65 years~* HbA1c of 5.5 - 7.7% at screening visit~* BMI 18-35 kg/m2~* Willingness to follow all study procedures, including attending all clinic visits~* Willingness to sign informed consent and HIPAA documents~Exclusion Criteria:~* Pregnancy or Lactation: For women of childbearing potential: there is a requirement for a negative urine pregnancy test.~* Renal insufficiency (serum creatinine of 2.0 mg/dL or greater).~* Serum ALT or AST equal to or greater than 3 times the upper limit of normal; hepatic synthetic insufficiency as defined as a serum albumin of less than 3.3 g/dL; or serum bilirubin of over 2.~* Hematocrit of less than or equal to 34%.~* Congestive heart failure, NYHA class II, III or IV.~* Coronary artery or cerebrovascular disease.~* Active foot ulceration.~* Active alcohol abuse, substance abuse, or severe mental illness (as judged by the principal investigator).~* Active malignancy, except basal cell or squamous cell skin cancers.~* Major surgical operation within 30 days prior to screening.~* Seizure disorder (epilepsy).~* Contraindication to an MRI scan, including having metallic splinters in the eye, a cardiac pacemaker, defibrillator, or any other ferromagnetic or electronically charged implanted device, or ferromagnetic clip(s) in the central nervous system.~* Currently administration of oral or parenteral corticosteroids.~* Use of an investigational drug within 30 days prior to screening.~* Bleeding disorder, treatment with warfarin, or platelet count below 50,000.~* History weight loss of ≥ 5 lbs over the prior month.~* Weight ≥ 300 lbs.~* Any concurrent illness, other than diabetes, that is not controlled by a stable therapeutic regimen.~* Any reason the principal investigator deems exclusionary.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Open-Label Glucagon (Type: EXPERIMENTAL): Subjects will receive 8 doses of glucagon, each dose will be 2.0 mcg per kg.

Based on this trial design, predict the completion outcome and termination type (if applicable).